Start Over

Ebola Virus Transmission Initiated by Relapse of Systemic Ebola Virus Disease.

Authors :: Mbala-Kingebeni P
Pratt C
Mutafali-Ruffin M
Pauthner MG
Bile F
Nkuba-Ndaye A
Black A
Kinganda-Lusamaki E
Faye M
Aziza A
Diagne MM
Mukadi D
White B
Hadfield J
Gangavarapu K
Bisento N
Kazadi D
Nsunda B
Akonga M
Tshiani O
Misasi J
Ploquin A
Epaso V
Sana-Paka E
N'kasar YTT
Mambu F
Edidi F
Matondo M
Bula Bula J
Diallo B
Keita M
Belizaire MRD
Fall IS
Yam A
Mulangu S
Rimoin AW
Salfati E
Torkamani A
Suchard MA
Crozier I
Hensley L
Rambaut A
Faye O
Sall A
Sullivan NJ
Bedford T
Andersen KG
Wiley MR
Ahuka-Mundeke S
Muyembe Tamfum JJ
Source :: The New England journal of medicine [N Engl J Med] 2021 Apr 01; Vol. 384 (13), pp. 1240-1247.
Publication Year :: 2021
Abstract: During the 2018-2020 Ebola virus disease (EVD) outbreak in North Kivu province in the Democratic Republic of Congo, EVD was diagnosed in a patient who had received the recombinant vesicular stomatitis virus-based vaccine expressing a ZEBOV glycoprotein (rVSV-ZEBOV) (Merck). His treatment included an Ebola virus (EBOV)-specific monoclonal antibody (mAb114), and he recovered within 14 days. However, 6 months later, he presented again with severe EVD-like illness and EBOV viremia, and he died. We initiated epidemiologic and genomic investigations that showed that the patient had had a relapse of acute EVD that led to a transmission chain resulting in 91 cases across six health zones over 4 months. (Funded by the Bill and Melinda Gates Foundation and others.).<br /> (Copyright © 2021 Massachusetts Medical Society.)